Pilot Study of the Antiviral Activity of Multiple Doses of Oral Lobucavir in AIDS Patients

Inclusion Criteria Concurrent Medication: Allowed: Aerosolized pentamidine. TMP / SMX. Isoniazid. Dapsone. Fluconazole. Ketoconazole. Rifabutin. Fluoxetine HCl. Acetaminophen. Antacids. Metamucil. Multivitamins. Other drugs with approval from sponsor. Patients must have: AIDS. CD4 count < 200 cells/mm3. Cytomegalovirus ( CMV ) viruria and virosemenia. No evidence of intraocular CMV. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: Acute or chronic cardiovascular, pulmonary, renal, hepatic, pancreatic, hematologic, endocrine, neurological, or other unstable illness. Inability to take oral medication. Allergy to nucleoside analogs. Diarrheal illness. Poor venous access. Positive test for drugs of abuse. Any other condition that would render patient unsuitable for study. Patients with the following prior conditions are excluded: History of pancreatitis. Recent diarrheal illness. History of weight loss. Acute serious illness within 4 weeks prior to study entry. Prior Medication: Excluded within 4 weeks prior to study entry: Erythropoietin. Any agent with anti-CMV activity. Other investigational agents. Prior Treatment: Excluded within 4 weeks prior to study entry: Surgery. Blood transfusion. Drug abuse.